Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical TechnologyKOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.Clinical DataMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalryNext: AZ claims another win for Imfinzi in frontline liver cancer Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
